Reporting from ESMO 2019 Congress, Johann de Bono comments on practice changing results presented in metastatic castration-resistant prostate cancer (mCRPC).
He features the results from the CARD study on best sequence treatment and from the PROfound trial with olaparib in patients whose tumours have homologous recombination repair gene alterations. He explains the need for molecular profiling of advanced prostate cancer which may have a major impact on prostate cancer management in the future.
Abstracts:
- LBA13_PR: CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration- resistant prostate cancer
- LBA12_PR: PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
This video was supported with an educational grant from Janssen. The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.